The HIV latency reversing agent HODHBt inhibits the phosphatases PTPN1 and PTPN2

JCI Insight. 2024 Aug 8;9(18):e179680. doi: 10.1172/jci.insight.179680.

Abstract

Nonreceptor tyrosine phosphatases (NTPs) play an important role in regulating protein phosphorylation and have been proposed as attractive therapeutic targets for cancer and metabolic diseases. We have previously identified that 3-Hydroxy-1,2,3-benzotriazin-4(3H)-one (HODHBt) enhanced STAT activation upon cytokine stimulation, leading to increased reactivation of latent HIV and effector functions of NK and CD8 T cells. Here, we demonstrate that HODHBt interacted with and inhibited the NTPs PTPN1 and PTPN2 through a mixed inhibition mechanism. We also confirm that PTPN1 and PTPN2 specifically controlled the phosphorylation of different STATs. The small molecule ABBV-CLS-484 (AC-484) is an active site inhibitor of PTPN1 and PTPN2 currently in clinical trials for advanced solid tumors. We compared AC-484 and HODHBt and found similar effects on STAT5 and immune activation, albeit with different mechanisms of action leading to varying effects on latency reversal. Our studies provide the first specific evidence to our knowledge that enhancing STAT phosphorylation via inhibition of PTPN1 and PTPN2 is an effective tool against HIV.

Keywords: AIDS/HIV; Cytokines; Phosphoprotein phosphatases; Signal transduction.

MeSH terms

  • HIV Infections / drug therapy
  • HIV-1* / drug effects
  • Humans
  • Phosphorylation / drug effects
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1* / antagonists & inhibitors
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1* / metabolism
  • Protein Tyrosine Phosphatase, Non-Receptor Type 2* / genetics
  • Protein Tyrosine Phosphatase, Non-Receptor Type 2* / metabolism
  • Triazines
  • Virus Latency* / drug effects

Substances

  • Protein Tyrosine Phosphatase, Non-Receptor Type 2
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • PTPN2 protein, human
  • PTPN1 protein, human
  • HODHBt
  • Triazines